Hui Yang

Dr. Hui Yang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Experimental and Molecular Pathology
Verified
Journal Article
Open access
MZMei Zhang
Mei Zhang
XKXue Kong
Xue Kong
CWChenlu Wu
Chenlu Wu
JLJiuhong Li
Jiuhong Li
HYHui Yang
Hui Yang
LHLingzhi Huang
Lingzhi Huang
Ischemic cardiomyopathy (ICM) is a significant global public health issue, with its pathophysiology encompassing atherosclerotic plaque formation, thrombosis, hypoperfusion, ischemic cell death, and left ventricular remodeling. Lactate is not only regarded as an energy metabolite but also acts as a signaling molecule that influences various physiological processes, regulating metabolism and muscle contraction. Lactylation, an emerging epigenetic modification, affects protein functionality and gene expression through the P300 enzyme. In ICM, lactate accumulation leads to pH imbalance and myocardial cell dysfunction, impacting cellular signaling. This paper will analyze the role of lactylation in ICM, focusing on coronary artery disease (ASCVD) and myocardial infarction (MI). It will also explore the differential expression and immunological characteristics of lactylation-related genes in normal and ICM tissues, providing potential targets for future research.

26 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
STShi Tai
Shi Tai
JTJianjun Tang
Jianjun Tang
BYBilian Yu
Bilian Yu
LTLiang Tang
Liang Tang
YWYang Wang
Yang Wang
SZShenghua Zhou
Shenghua Zhou
Background: Information regarding the impact of cardiovascular disease (CVD) on disease progression among patients with mild coronavirus disease 2019 (COVID-19) is limited. Methods: This study evaluated the association of underlying CVD with disease progression in patients with mild COVID-19. The primary outcome was the need to be transferred to intensive care due to disease progression. The patients were divided with and without CVD as well as stable and intensive care groups. Results: Of 332 patients with mild COVID-19, median age was 51 years (IQR, 40-59 years), and 200 (61.2%) were female. Of 48 (14.5%) patients with CVD, 23 (47.9%) progressed to severe disease status and required intensive care. Compared with patients without CVD, patients with CVD were older, and more likely to have fatigue, chest tightness, and myalgia. The rate of requiring intensive care was significantly higher among patients with CVD than in patients without CVD (47.92% vs. 12.4%; P<0.001). In subgroup analysis, rate of requiring intensive care was also higher among patients with either hypertension or coronary heart disease than in patients without hypertension or coronary heart disease. The multivariable regression model showed CVD served as an independent risk factor for intensive care (Odd ratio [OR], 2.652 [95% CI, 1.019-6.899]) after adjustment for various cofounders. Conclusions: Patients with mild COVID-19 complicating CVD in are susceptible to develop severe disease status and requirement for intensive care. Key Points: Question: What is the impact of coexisting cardiovascular diseases (CVD) on disease progression in patients with mild COVID-19? Findings: Although most patients with mild COVID-19 were discharged alive from hospital, approximately 47.9% patients with coexisting CVD developed severe disease status and required intensive care. CVD is an independent risk factor of intensive care among patients with mild COVID-19. Meaning: Coexisting CVD is associated with unfavorable outcomes among patients with mild COVID-19. Special monitoring is required for these patients to improve their outcome.

15 April 2026 in Comprehensive Physiology
Verified
Journal Article
Open access
YZYunlong Zhu
Yunlong Zhu
JFJie Fan
Jie Fan
LTLiang Tang
Liang Tang
YZYuying Zhou
Yuying Zhou
KJKang Jiang
Kang Jiang
SZShenghua Zhou
Shenghua Zhou
Background: Membrane‐associated RING‐CH1 (MARCH1) is a critical membrane‐bound RING domain E3 ubiquitin ligase that primarily regulates immune cell development, immune responses, antigen presentation modulation, and metabolic functions. Its role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF) remains elusive. This study aimed to investigate the function of MARCH1 in HFpEF. Methods: Multi‐hit (high fat/sugar diet together with deoxycorticosterone acetate and angiotensin II injection) HFpEF mouse model was established in C57BL/6 wild‐type mice and MARCH1 KO mice. Non‐HFpEF control mice received standard diet. Comprehensive evaluation was carried out through echocardiography, histological and biochemical studies. White adipose tissue (WAT) beiging was analyzed in isolated stromal vascular fraction cells. The relevant molecular mechanisms were determined through RNA sequencing and co‐immunoprecipitation assay. Results: Cardiometabolic dysregulation with hypertension and obesity was observed in WT HFpEF mice. Significantly reduced running distance and running time were found in HFpEF mice compared to the WT control mice (both p < 0.05). Histologic and echocardiographic examinations also visualized cardiac fibrosis, left ventricular hypertrophy, and diastolic dysfunction in HFpEF mice. MARCH1 expression was significantly upregulated in the WAT of HFpEF mice. MARCH1 deficiency alleviated cardiac dysfunction of HFpEF mice and induced WAT beiging following HFpEF. Mechanistically, MARCH1 contributes to HFpEF by direct binding to Krüppel‐like factor 15 (KLF15). Overexpressing KLF15 blocked the beiging effects of WAT from MARCH1 KO mice. Conclusion: Our study highlights the positive anti‐fibrotic and WAT beiging effects of MARCH1 inhibition in the setting of HFpEF. Targeting MARCH1 and KLF15 might serve as novel therapeutic options for HFpEF.